SCHEMBL4902637

SCHEMBL4902637

CCC(C(=O)O)[C@H](N)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.48
SLC7A5 Q01650 2/20 0.48
SLC1A1 P43005 7/20 0.47
SLC1A3 P43003 5/20 0.47
SLC1A2 P43004 5/20 0.47
TDP1 Q9NUW8 2/20 0.40
CHRM1 P11229 1/20 0.40
AKR1A1 P14550 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
ADRA1A P35348 1/20 0.40
HRH1 P35367 1/20 0.40
DRD3 P35462 1/20 0.40
SLC6A3 Q01959 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
GRIK1 P39086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8982021 1.00 GLO1 (0.48) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL19525723 1.00 GLO1 (0.48) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL30626325 1.00 GLO1 (0.48) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
Hydrochloric Acid SCHEMBL11872242 0.97 GLO1 (0.47) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
Hydrochloric Acid SCHEMBL9305761 0.97 GLO1 (0.47) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL5322674 0.85 SLC7A5 (0.44) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL2485256 0.85 SLC7A5 (0.44) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL27927148 0.83 SLC1A3 (0.39) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL11771843 0.81 SLC1A3 (0.44) GLO1SLC7A5SLC1A1SLC1A3SLC1A2
SCHEMBL28051218 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114984296-A Thermally induced hydrogel embolic agent with X-ray developing capability and application thereof 复旦大学 2022-09-02 CN disclosed
US-7592168-B2 Cephalosporin C acylase mutant and method for preparing 7-ACA using same SANDOZ AG (CH) 2009-09-22 US disclosed
US-20080003288-A1 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2008-01-03 US disclosed
US-7204997-B2 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2007-04-17 US disclosed
EP-1478403-A1 RESPONSIVE MICROGEL AND METHODS RELATED THERETO SUPRATEK PHARMA, INC. (CA) 2004-11-24 EP disclosed
US-20030152623-A1 Responsive microgel and methods related thereto SUPRATEK PHARMA INC. (CA) 2003-08-14 US disclosed
WO-2003063909-A1 RESPONSIVE MICROGEL AND METHODS RELATED THERETO SUPRATEK PHARMA INC. (US) 2003-08-07 WO disclosed
EP-0910351-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-28 EP disclosed
EP-0907666-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-14 EP disclosed
WO-1997049736-A2 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
WO-1997049387-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
US-3934027-A 18β-Glycyrrhetinic acid amides useful as antiulcer agents PFIZER INC. (US) 1976-01-20 US disclosed